While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug.
Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) said Wednesday it had raised a $62 million series B round to fund a Phase III trial of STS101, its dry powder formulation of dihydroergotamine (DHE) and intranasal delivery system, to treat acute migraine. The placebo-controlled study is to begin in 3Q19.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,